UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chimeric Antigen Receptor T Cells Redirected Towards Clonally Restricted Surface Immunoglobulin Efficiently Eradicate Mature B Lymphocyte-Derived Malignancies

Blood, 2018-11, Vol.132 (Supplement 1), p.337-337

Ranganathan, Raghuveer

2018

Volltextzugriff (PDF)

Chimeric antigen receptor T cells targeting the lambda light chain of human immunoglobulin as a viable target for B cell non-Hodgkin lymphoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.12079-12079

Ranganathan, Raghuveer

2018

Volltextzugriff (PDF)

Adoptive T cell therapy: Boosting the immune system to fight cancer

Seminars in immunology, 2020-06, Vol.49, p.101437-101437, Article 101437

2020

Volltextzugriff (PDF)

Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology

Advanced drug delivery reviews, 2022-09, Vol.188, p.114421-114421, Article 114421

2022

Volltextzugriff (PDF)

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

Cancer research (Chicago, Ill.), 2016-03, Vol.76 (6), p.1578-1590

2016

Volltextzugriff (PDF)

CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells

Clinical cancer research, 2021-11, Vol.27 (21), p.5951-5960

2021

Volltextzugriff (PDF)

Outcomes of Neutropenic Patients with Severe Infections Treated with Granulocyte Transfusions: The USC Experience

Blood, 2023-11, Vol.142 (Supplement 1), p.5564-5564

2023

Volltextzugriff (PDF)

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor―Transduced Human T cells in Solid Tumors

Clinical cancer research, 2014-08, Vol.20 (16), p.4262-4273

2014

Volltextzugriff (PDF)

Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer

Clinical cancer research, 2016-01, Vol.22 (2), p.436-447

2016

Volltextzugriff (PDF)

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Blood, 2022-11, Vol.140 (Supplement 1), p.9446-9447

2022

Volltextzugriff (PDF)

The Limitations and Promise of Immunotherapy With Chimeric Antigen-Modified T Cells

Oncology (Williston Park, N.Y.), 2016-10, Vol.30 (10), p.889-890

2016

Volltextzugriff (PDF)

Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma

Leukemia & lymphoma, 2021-01, Vol.62 (1), p.68-75

2021

Volltextzugriff (PDF)

Abstract 4706: TCR engineered adoptive T-cell therapy for lung cancer is augmented by combined PD1 and TIM3 antibody blockade

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4706-4706

2015

Volltextzugriff (PDF)

Multifactorial T cell Hypofunction that is Reversible Can Limit the Efficacy of Chimeric Antibody Receptor-transduced Human T cells in Solid Tumors

Clinical cancer research, 2014-06, Vol.20 (16), p.4262-4273

2014

Volltextzugriff (PDF)

Validation of the European Practice Guidelines for the Use of Recombinant Activated Factor VII In Patients with Massive Bleeding

Blood, 2010-11, Vol.116 (21), p.4744-4744

2010

Volltextzugriff (PDF)

Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas

Novel Therapeutics for Rare Lymphomas, 2019, p.27-46

2019

Volltextzugriff (PDF)

Novel Agents in Primary Central Nervous System Lymphoma

Novel Therapeutics for Rare Lymphomas, 2019, p.119-135

2019

Volltextzugriff (PDF)

1 – 17 von 17

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(15)

Publikationsform

Artikel
(15)
Buchkapitel
(2)

Sprache

Englisch
(17)

Erscheinungsjahr

n.n

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chimeric Antigen Receptor T Cells Redirected Towards Clonally Restricted Surface Immunoglobulin Efficiently Eradicate Mature B Lymphocyte-Derived Malignancies

Chimeric antigen receptor T cells targeting the lambda light chain of human immunoglobulin as a viable target for B cell non-Hodgkin lymphoma

Adoptive T cell therapy: Boosting the immune system to fight cancer

Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells

Outcomes of Neutropenic Patients with Severe Infections Treated with Granulocyte Transfusions: The USC Experience

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor―Transduced Human T cells in Solid Tumors

Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

The Limitations and Promise of Immunotherapy With Chimeric Antigen-Modified T Cells

Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma

Abstract 4706: TCR engineered adoptive T-cell therapy for lung cancer is augmented by combined PD1 and TIM3 antibody blockade

Multifactorial T cell Hypofunction that is Reversible Can Limit the Efficacy of Chimeric Antibody Receptor-transduced Human T cells in Solid Tumors

Validation of the European Practice Guidelines for the Use of Recombinant Activated Factor VII In Patients with Massive Bleeding

Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas

Novel Agents in Primary Central Nervous System Lymphoma

Suchergebnisse filtern